Kura Oncology (NASDAQ:KURA) Stock: Insider Troy Edward Wilson Acquires 98,881 Shares

by · The Cerbat Gem

Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) CEO Troy Wilson purchased 98,881 shares of the business’s stock in a transaction dated Friday, November 13th. The stock was bought at an average price of $7.63 per share, for a total transaction of $754,462.03. Following the completion of the acquisition, the chief executive officer owned 534,337 shares of the company’s stock, valued at approximately $4,076,991.31. The trade was a 22.71% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.

Troy Edward Wilson also recently made the following trade(s):

  • On Monday, November 16th, Troy Wilson purchased 101,119 shares of Kura Oncology stock. The stock was bought at an average cost of $7.42 per share, for a total transaction of $750,302.98.
  • On Monday, August 24th, Troy Wilson acquired 100,000 shares of Kura Oncology stock. The shares were bought at an average price of $12.39 per share, with a total value of $1,239,000.00.

Kura Oncology Stock Down 8.8%

Kura Oncology stock traded down $0.68 during trading hours on Monday, hitting $7.09. The company had a trading volume of 2,621,535 shares, compared to its average volume of 2,345,466. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.60 and a quick ratio of 4.71. Kura Oncology, Inc. has a 1 year low of $6.75 and a 1 year high of $13.90. The company has a 50-day moving average price of $10.05 and a two-hundred day moving average price of $9.76.

Kura Oncology (NASDAQ:KURA – Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.78) EPS for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.04. The business had revenue of $22.84 million for the quarter, compared to the consensus estimate of $24.94 million. Kura Oncology had a negative net margin of 369.26% and a negative return on equity of 336.24%. On average, analysts forecast that Kura Oncology, Inc. will post -3.20 earnings per share for the current year.

Institutional Trading of Kura Oncology

A number of institutional investors have recently made changes to their positions in the business. IFP Advisors Inc boosted its position in shares of Kura Oncology by 136.5% in the 2nd quarter. IFP Advisors Inc now owns 2,542 shares of the company’s stock worth $28,000 after purchasing an additional 1,467 shares in the last quarter. Sterling Capital Management LLC increased its position in Kura Oncology by 842.5% during the 3rd quarter. Sterling Capital Management LLC now owns 2,818 shares of the company’s stock valued at $30,000 after buying an additional 2,519 shares in the last quarter. Physician Wealth Advisors Inc. acquired a new position in Kura Oncology during the 3rd quarter valued at about $43,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Kura Oncology in the third quarter valued at about $49,000. Finally, Allworth Financial LP purchased a new stake in Kura Oncology in the second quarter valued at about $113,000.

Analyst Ratings Changes

Several research analysts recently issued reports on KURA shares. Deutsche Bank set a $24.00 price objective on Kura Oncology in a research note on Wednesday, October 14th. UBS Group set a $24.00 target price on Kura Oncology in a research report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research report on Thursday, October 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a report on Wednesday, October 14th. Finally, JPMorgan Chase & Co. started coverage on Kura Oncology in a research report on Thursday, October 1st. They set an “overweight” rating and a $30.00 price target on the stock. Eleven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.88.

Read Our Latest Research Report on KURA

About Kura Oncology

(Get Free Report)

Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company’s best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.

Featured Articles